MS drugTysabri delivers growth for Elan in 2011

Concerns that Elan numbers might be hit by European government austerity measures appeared to have been unfounded, with the company reporting better than expected full year results.

12th February, 2011

Concerns that Elan numbers might be hit by European government austerity measures appeared to have been unfounded, with the company reporting better than expected full year results. The pharmaceutical stock has also forecast strong growth for the year ahead.

The company is on track to become profitable this year and will also become modestly cash-generative. Analysis by Davy stockbrokers said that its MS drug Tysabri is now becoming ‘‘a significant and highly profitable MS therapy’’....

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

The year in review

Legacy Richie Oakley 1 year ago

Newsround: What Thursday’s papers say

Legacy Leanna Byrne 5 years ago

More cycle routes, expansion of Luas to Bray and new bus network proposed

Legacy Digital Desk 5 years ago